Kodiak Sciences Inc. (KOD)
$
9.04
+0.07 (0.77%)
Key metrics
Financial statements
Free cash flow per share
-2.1918
Market cap
476.5 Million
Price to sales ratio
17.8789
Debt to equity
0.9278
Current ratio
3.4800
Income quality
0.5754
Average inventory
0
ROE
-1.1307
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, focuses on the research and development of therapeutics aimed at addressing retinal diseases. Its lead product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer currently undergoing Phase IIb/III clinical studies for the treatment of wet age-related macular degeneration (AMD) and other conditions such as diabetic macular edema and non-proliferative diabetic retinopathy. The EBITDA ratio is 0.00 highlighting the company's operational efficiency. The company recorded an operating income of -$186,849,000.00 reflecting its earnings from core operations, while the operating income ratio is 0.00 indicating the company's operational profitability margin. Additionally, it incurred an interest expense of $0.00 reflecting its debt servicing obligations. The net total of other income and expenses is $10,642,000.00 which reflects non-core financial activities. Alongside KSI-301, Kodiak is advancing other preclinical stage product candidates, including KSI-501, a bispecific conjugate targeting retinal diseases with an inflammatory component, and KSI-601, which is a triplet inhibitor designed to treat dry AMD. Originally known as Oligasis, LLC, the company rebranded to Kodiak Sciences Inc. in September 2015 and was incorporated in 2009, with its headquarters based in Palo Alto, California. The stock is affordable at $5.17 making it an attractive option for budget-conscious investors. With a market capitalization of $476,544,323.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, the stock has a low average trading volume of 517,234.00 indicating lower market activity. Kodiak Sciences Inc. belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical field as it seeks to develop and commercialize promising treatments for retinal diseases.
Is Kodiak Sciences Inc. (KOD) a good investment?
Investing in Kodiak Sciences Inc. (KOD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Kodiak Sciences Inc. (KOD)'s stock forecast?
Analysts predict Kodiak Sciences Inc. stock to fluctuate between $1.92 (low) and $11.60 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Kodiak Sciences Inc.'s market capitalization?
As of 2025-08-29, Kodiak Sciences Inc.'s market cap is $476,544,323, based on 52,715,080 outstanding shares.
How does Kodiak Sciences Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Kodiak Sciences Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Kodiak Sciences Inc. (KOD) stock?
To buy Kodiak Sciences Inc. (KOD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for KOD. Place an order (Market, Limit, etc.).
What is the best time to invest in Kodiak Sciences Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Kodiak Sciences Inc. stock ever split?
Kodiak Sciences Inc.'s last stock split was 5:1 on 2022-02-23.
How did Kodiak Sciences Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$3.35 | Growth: -32.60%.
Where can I find Kodiak Sciences Inc.'s investor relations reports?
Visit https://kodiak.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Kodiak Sciences Inc.?
You can explore historical data from here
What is the all-time high and low for Kodiak Sciences Inc. stock?
All-time high: $131.97 (2021-11-05) | All-time low: $1.37 (2023-10-27).
What are the key trends affecting Kodiak Sciences Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025.
prnewswire.com
PALO ALTO, Calif. , Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present the Company's pipeline programs in glaucoma at the American Chemical Society (ACS) Fall 2025 Meeting on Tuesday, August 19, 2025, in Washington, D.C.
zacks.com
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
prnewswire.com
PALO ALTO, Calif. , June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management along with key opinion leaders will present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de Janeiro, Brazil on Friday, June 27, 2025.
zacks.com
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
zacks.com
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
zacks.com
Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
seekingalpha.com
Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027.
See all news
